Proqr Therapeutics NV Schedule 13D activist filings

Van Herk Investments and other shareholders have filed a petition with the Dutch Enterprise Chamber seeking an investigation into ProQR Therapeutics' corporate governance and requesting the appointment of an independent director.

Van Herk Investments B.V. and affiliated entities have updated their Schedule 13D filing, reporting a 10.9% ownership in ProQR Therapeutics N.V. following a recent share issuance.

Van Herk Investments B.V. announced its intention to vote against key share capital increase and authorization proposals at ProQR Therapeutics N.V.'s upcoming Annual General Meeting, citing concerns over potential dilution and governance.

Van Herk Investments B.V. and its affiliates have increased their beneficial ownership in ProQR Therapeutics N.V. to 14.6% through recent open market purchases.

Van Herk Investments B.V. and its affiliated entities have increased their beneficial ownership in ProQR Therapeutics N.V. to 13.6% through recent open market purchases.

Van Herk Investments B.V. and its affiliates have increased their beneficial ownership in ProQR Therapeutics N.V. to 12.6% through recent open market purchases.

Van Herk Investments, holding 11.6% of ProQR Therapeutics, escalated its corporate governance concerns, demanding board changes and adherence to Dutch corporate governance standards.

Van Herk Investments, a significant shareholder in ProQR Therapeutics N.V., has filed a Schedule 13D to publicly challenge the proposed reappointments of two key board members, citing breaches of corporate governance and disappointing company performance.